Clinical TrialJul 27, 2026, 06:48 PM
CG Oncology Publishes Positive Phase 3 BOND-003 Trial Results in Lancet Oncology
AI Summary
CG Oncology announced the publication of positive results from its pivotal Phase 3 BOND-003 Cohort C trial in The Lancet Oncology. The trial evaluated cretostimogene grenadenorepvec monotherapy for high-risk, BCG-unresponsive non-muscle invasive bladder cancer, demonstrating a 75.5% complete response rate and a median duration of response of at least 27.9 months. The therapy also showed favorable safety, high rates of bladder preservation, and meaningful progression-free survival, positioning it as a potential bladder-sparing treatment.
Key Highlights
- 75.5% complete response rate achieved at any time in BOND-003 Cohort C.
- Median duration of response (DOR) is at least 27.9 months and ongoing.
- 12-month DOR was 64.2%, and 24-month DOR was 60.1%.
- Approximately 89% of patients maintained bladders at 12 months, 81% at 24 months.
- 96.6% of patients were free from progression to muscle invasive bladder cancer at 96 weeks.
- No Grade 3 or greater treatment-related adverse events or discontinuations reported.
Price Impact
More from CGON